There were no baseline differences in demographic, clinical, health literacy or any belief measure between responders and non-responders.
Differences on imagery and other baseline measures between 'responders' and 'non-responders' in the positive condition were compared by using two-tailed independent samples t tests or chi-square tests of independence.
Further, there were no correlations between P-5-HT levels and any of the outcome measures or differences between responders and non-responders to treatment.
HCU, socio-demographic variables, reception of social grants, and type of medical aid were measured, and compared between responders who used health care services with those who did not.
On the contrary, most parameters of the inflammatory mediators measured here did not differ between responders and nonresponders – although IL-8 was, on an average, higher in the responder group [ 21].
There was no significant difference in serum testosterone levels, measured 4 weeks after testosterone implantation, between responders and nonresponders.
For the primary outcome measure Global Perceived Effect (GPE) a selection can be made between responders (positive effect) and non-responders (no or negative effect) to the treatment received.
For negative items of the PIT, there was no difference between vividness ratings for responders, M = 32.86, SD = 7.43 or non-responders, M = 26.17, SD = 13.20; t(11) < 1. Conversely, there were no significant differences between responders and non-responders on any other pre-treatment measures or demographic characteristics (all p >.10), with the exception of gender.
Percentage change in tumor size as measured on CT from baseline to post-cycle 1 imaging differed significantly between responders and non-responders (P = 0.016).
There were statistically significant differences in the CRP and NLR changes between responders and those with progressive disease (all p < 0.001, repeated measures ANOVA).
